PMID- 28918389
OWN - NLM
STAT- MEDLINE
DCOM- 20180910
LR  - 20180910
IS  - 1708-8267 (Electronic)
IS  - 1081-5589 (Linking)
VI  - 66
IP  - 1
DP  - 2018 Jan
TI  - Glucagon like peptide-1 receptor agonists for the management of obesity and 
      non-alcoholic fatty liver disease: a novel therapeutic option.
PG  - 7-10
LID - 10.1136/jim-2017-000554 [doi]
AB  - Obesity is a major risk factor for the development of type 2 diabetes mellitus 
      (T2DM), and is associated with a cluster of metabolic factors that lead to poor 
      cardiovascular outcomes. In non-alcoholic fatty liver disease (NAFLD), liver fat 
      (triglyceride) accumulation closely mirrors adipose tissue dysfunction and 
      insulin resistance in obesity and T2DM. It is now recognized as the most common 
      chronic liver disease in Westernized societies, often progressing to more severe 
      forms of the disease such as nonalcoholic steatohepatitis (NASH), or cirrhosis 
      and hepatocellular carcinoma. However, NAFLD remains largely overlooked by 
      healthcare providers although it affects about two-thirds of patients with 
      obesity and it promotes the development of T2DM. NAFLD mirrors adipose tissue and 
      systemic insulin resistance, the liver being a 'barometer' of metabolic health. 
      Although pioglitazone is emerging as the treatment of choice for NASH in patients 
      with insulin-resistance, or those with T2DM, many other options are being tested. 
      Due to their overall safety and efficacy, glucagon-like peptide-1 receptor 
      agonists (GLP-1 RAs) are becoming one of the cornerstones for the management of 
      both obesity and T2DM, and a novel alternative for the treatment of NAFLD. In 
      this review, we will briefly summarize the status of GLP-1RA for the treatment of 
      obesity and NAFLD.
CI  - (c) American Federation for Medical Research (unless otherwise stated in the text 
      of the article) 2018. All rights reserved. No commercial use is permitted unless 
      otherwise expressly granted.
FAU - Dhir, Gauri
AU  - Dhir G
AD  - Division of Endocrinology, Diabetes and Metabolism, University of Florida, 
      Gainesville, Florida, USA.
AD  - Division of Endocrinology, Diabetes and Metabolism, Malcom Randall VA Medical 
      Center, Gainesville, Florida, USA.
FAU - Cusi, Kenneth
AU  - Cusi K
AD  - Division of Endocrinology, Diabetes and Metabolism, University of Florida, 
      Gainesville, Florida, USA.
AD  - Division of Endocrinology, Diabetes and Metabolism, Malcom Randall VA Medical 
      Center, Gainesville, Florida, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170915
PL  - England
TA  - J Investig Med
JT  - Journal of investigative medicine : the official publication of the American 
      Federation for Clinical Research
JID - 9501229
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
SB  - IM
MH  - Animals
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Humans
MH  - Models, Biological
MH  - Non-alcoholic Fatty Liver Disease/*drug therapy
MH  - Obesity/*drug therapy
OTO - NOTNLM
OT  - GLP-1
OT  - NASH
OT  - fatty liver
OT  - obesity
OT  - steatosis
OT  - type 2 diabetes mellitus
COIS- Competing interests: None declared.
EDAT- 2017/09/18 06:00
MHDA- 2018/09/11 06:00
CRDT- 2017/09/18 06:00
PHST- 2017/08/12 00:00 [accepted]
PHST- 2017/09/18 06:00 [pubmed]
PHST- 2018/09/11 06:00 [medline]
PHST- 2017/09/18 06:00 [entrez]
AID - jim-2017-000554 [pii]
AID - 10.1136/jim-2017-000554 [doi]
PST - ppublish
SO  - J Investig Med. 2018 Jan;66(1):7-10. doi: 10.1136/jim-2017-000554. Epub 2017 Sep 
      15.